Filed Pursuant to Rule 424(b)(3)
Registration No. 333-267127
(To Prospectus dated November 10, 2022)
YOUR VOTE IS VERY IMPORTANT
To the Stockholders of Yumanity Therapeutics, Inc. and Shareholders of Kineta, Inc.:
Since the filing of our proxy statement/prospectus/information statement with the United States Securities and Exchange Commission (the “SEC”), Yumanity Therapeutics, Inc. (“Yumanity”), Kineta, Inc. (“Kineta”) and Yacht Merger Sub, Inc., a wholly-owned subsidiary of Yumanity (“Merger Sub”) entered into the First Amendment to Merger Agreement (the “Amendment to Merger Agreement”), which amends that certain Agreement and Plan of Merger, dated June 5, 2022 (the “Merger Agreement”) pursuant to which Merger Sub will merge with and into Kineta, with Kineta surviving as a wholly-owned subsidiary of Yumanity (the “Merger”). In addition, since the filing of our proxy statement/prospectus/information statement with the SEC, Yumanity, Kineta and certain institutional investors (the “PIPE Investors”) entered into Amendment No. 2 to the Securities Purchase Agreement, which amends that certain Securities Purchase Agreement (as amended, the “Securities Purchase Agreement”) pursuant to which, among other things, Yumanity agreed to issue to the PIPE Investors shares of Yumanity common stock in a private placement transaction for an aggregate purchase price of approximately $30.0 million (the “Private Placement”). We are furnishing this supplement to our proxy statement/prospectus/information statement to:
provide supplemental disclosures regarding the Merger to reflect the Amendment to Merger Agreement;
provide supplemental disclosures regarding the Private Placement to reflect the Amendment No. 2 to the Securities Purchase Agreement and to revise Proposal No. 3 to, among other things, remove references to the number of shares and purchase price of Yumanity common stock to be issued to the PIPE Investors in the Private Placement;
provide supplemental disclosures for additional updates since the filing of the proxy statement/prospectus/information statement, including, among other things, disclosures relating to Kineta’s business with respect to the reduction in force by Kineta of 12 full-time and two part-time employees and the resignation of Jiyoung Hwang from the Kineta board of directors; and
provide a revised proxy card, reflecting revisions to Proposal No. 3 therein.
The Yumanity special meeting will still be held in a virtual-only format via live audio webcast at 10:00 a.m., Eastern Time, on December 13, 2022 at www.virtualshareholdermeeting.com/YMTX2022SM, unless postponed or adjourned to a later date.
The following pages include an Amended and Restated Notice of the Special Meeting, a supplement to the proxy statement/prospectus/information statement, including a revised Proposal No. 3, and a revised proxy card. You should read this supplement to our proxy statement/prospectus/information statement in conjunction with the proxy statement/prospectus/information statement, dated November 10, 2022. Our proxy statement/prospectus/information statement dated November 10, 2022 contains important information regarding Proposal Nos. 1, 2, 4, 5, 6, 7 and 8 submitted to Yumanity’s stockholders which have not been revised by this supplement to the proxy statement/prospectus/information statement, as well as additional important information for Yumanity’s stockholders. If you previously submitted a proxy card or voting instruction form or submitted a proxy or voting instructions by Internet or telephone, then your previous voting instructions will continue to be honored with respect to the shares held by you with respect to all Proposals, including revised Proposal No. 3.
Yumanity and Kineta are excited about the opportunities the Merger brings to both Yumanity and Kineta securityholders, and thank you for your consideration and continued support.
Richard Peters, M.D., Ph.D.
President and Chief Executive Officer
Yumanity Therapeutics, Inc.
Shawn Iadonato, Ph.D.
Chief Executive Officer